Molecules that interfere with these interactions, especially those targeting JAK1 and JAK3, such as TNF antagonists (Jones-Hall and Nakatsu, 2016), have shown promising efficacy and safety in IBD treatment. The gene discussed is JAK3; the disease is inflammatory bowel disease.